Core Viewpoint - Yifan Pharmaceutical (002019) announced that some of its wholly-owned or controlled subsidiaries' self-owned or imported general distribution products have been included in the "2025 National Medical Insurance Directory" [1] Group 1: Product Inclusion - The innovative drug Aibegesitin α injection (Yilishu) and the imported general distribution product Dihyaluronic Acid Sodium Injection (Yinikon) have been renewed for inclusion in the directory [1] - The compound Huangdai tablets (Baixuekang) have been adjusted to the regular national medical insurance directory [1] - Other products already included in the national medical insurance directory by the company's subsidiaries did not experience any adjustments [1] Group 2: Clinical Trials - The company's wholly-owned subsidiary has received a clinical trial approval notice for the in-development product N-3C01 injection, allowing it to conduct clinical trials in patients with advanced solid tumors and non-muscle invasive bladder cancer [1]

证券代码：002019 证券简称：亿帆医药 公告编号：2025-068 亿帆医药股份有限公司 关于全资子公司在研产品 N-3C01 注射液获得临床试验批准 通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）全资子公司合肥欣竹生物科技 有限公司（以下简称"合肥欣竹"）于近日收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，同意合肥欣竹就在研创新大分子药物N-3C01注 射液（以下简称"N-3C01"）开展治疗晚期实体瘤和治疗非肌层浸润性膀胱癌 （NMIBC）的临床试验。现将相关情况公告如下： 注册分类：治疗用生物制品1类 一、药物临床试验批准通知书主要内容 产品名称：N-3C01注射液 产品研究代号：N-3C01 申请的适应症：晚期实体瘤、非肌层浸润性膀胱癌 剂型：注射液 申请事项：境内生产药品注册临床试验 申请类型：新药 受理号：CXSL2500832（晚期实体瘤）、 CXSL2500834（非肌层浸润性膀 胱癌） 通知书编号：2025LP03292（晚期实体瘤）、2025LP03298（非肌层浸 ...

证券代码：002019 证券简称：亿帆医药 公告编号：2025-067 亿帆医药股份有限公司 特此公告。 亿帆医药股份有限公司董事会 一、本次纳入国家医保目录药品基本情况 二、 对公司的影响及风险提示 上述产品继续纳入《2025年国家医保目录》，有利于促进开拓市场，提升产 品销量，短期内不会对公司的业绩产生重大影响，未来对公司经营业绩的影响目 前暂无法估计。除上述产品外，公司全资或控股子公司其他已纳入国家医保目录 的产品本次未发生调整变动。 《2025年国家医保目录》将于2026年1月1日起正式实施，医保支付标准、医 保报销细则等相关信息，需以国家医疗保障局等相关政府部门公示信息为准。敬 请广大投资者谨慎投资，注意防范投资风险。 关于公司产品纳入国家医保目录的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据2025年12月7日国家医保局、人力资源社会保障部发布的《国家基本医 疗保险、生育保险和工伤保险药品目录（2025年）》（以下简称"《2025年国家 医保目录》"），亿帆医药股份有限公司（以下简称"公司"）全资或控股子公 司部分自有或进口总经销产品 ...

Core Viewpoint - The company Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary Hefei Xinzhu Biotechnology Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of the innovative macromolecule drug N-3C01 injection, aimed at treating advanced solid tumors and non-muscle invasive bladder cancer [1] Group 1 - The N-3C01 drug is a recombinant IL-15/IL-15Rα fusion protein developed using DNA recombinant technology, which can activate the proliferation and killing functions of NK cells and cytotoxic T cells to achieve immune activation for tumor eradication [1] - As of the announcement date, similar target drugs have been approved in the United States and the United Kingdom, while no products targeting the same pathway have been approved for market in China [1] - The development and production cycle for this drug is long and involves multiple stages, leading to uncertainty regarding future approval for market release by the National Medical Products Administration [1]

摘要 / 创造新的增量 嘿嘿，周五没什么好的段子，就没发文，唯一一个我觉得好笑的就是，保险券商 异动股的时候，群里传出小作文，说"会议重提jzjx"! 盘后保险业务相关因子调整的文件出来了，谁又知道内幕抢跑了！ 《通知》明确： 1）险资持仓时间超过三年的沪深300指数成分股、中证红利低波动100指数 成分股的风险因子从0.3下调至0.27，持仓时间根据过去6年加权平均持仓时 间确定。 2）险资持仓时间超过两年的科创板上市普通股的风险因子从0.4下调至 0.36，持仓时间根据过去4年加权平均持仓时间确定。 3）保险公司出口信用保险业务和中国出口信用保险公司海外投资保险业务的 保费风险因子从0.467下调至0.42，准备金风险因子从0.605下调至0.545。 根据申万宏源，以9月末水平静态测算，本次调降险资股票投资风险因子合计给A 股上市险企带来200亿元最低资本优化，调整后核心/综合偿付能力充足率平均提 升1.5/2.1pct。假设调整风险因子后，A股上市险企维持偿付能力充足度不变， 沪深300成分股(持有3年以上)的潜在增配空间达789亿元。 没有增量，创造增量也要上！ 这个拼音缩写大概率是降准降息，哈哈哈 ...

Group 1: New Urbanization and Economic Development - The State Council emphasizes that new urbanization is a crucial vehicle for expanding domestic demand, promoting industrial upgrades, and strengthening the domestic circulation [2] - The government plans to implement urbanization strategies tailored to local conditions, focusing on optimizing the layout of people, industries, and cities [2] - There is a commitment to address issues related to the urbanization of agricultural migrants, including employment, social security, housing, and education for their children [2] Group 2: Infrastructure and Investment - The National Development and Reform Commission has expanded the scope of infrastructure REITs to include sports venues, commercial complexes, and urban renewal projects, marking a significant breakthrough in the types of underlying assets [4] - A total of 60 billion yuan has been allocated for the fourth batch of central budget investments aimed at creating job opportunities for low-income individuals through labor-intensive projects [5] Group 3: Financial Regulations and Market Dynamics - The China Securities Regulatory Commission plans to relax regulations for high-quality institutions, optimizing risk control indicators and capital space to enhance capital efficiency [5] - The People's Bank of China will conduct a 10 billion yuan reverse repurchase operation to maintain liquidity in the banking system [6] - Insurance companies have seen a reduction in risk factors for various business lines, encouraging improved long-term investment management capabilities [7] Group 4: Cultural and Tourism Integration - The Ministry of Culture and Tourism and the Civil Aviation Administration have issued an action plan to enhance the integration of cultural tourism and civil aviation, aiming for improved service levels and broader coverage of travel routes by 2027 [4] Group 5: International Trade and Economic Outlook - The OECD maintains its global economic growth forecasts at 3.2% for this year and 2.9% for next year, highlighting resilience but also risks such as trade barriers and fiscal vulnerabilities [9] - The U.S. private sector saw a decrease of 32,000 jobs in November, indicating a stagnation in job creation and a downward trend in wage growth [10]

Group 1 - Company’s subsidiary, Hangzhou Xinfu Technology Co., Ltd., received approval from the National Health Commission for 2'-Fucosyllactose as a food nutrition enhancer [1][2] - 2'-Fucosyllactose is a significant oligosaccharide found in breast milk, known for its benefits in regulating gut microbiota, promoting brain development, and enhancing immunity [1] - The approval allows the use of 2'-Fucosyllactose in various infant formula products, including those for special medical purposes [2] Group 2 - The approval marks a significant advancement in the application of synthetic biology for the company, laying a solid foundation for future product commercialization [3] - The company has adjusted guarantee limits among its subsidiaries, reallocating unused guarantee amounts to support business development needs [5][6] - The company provided guarantees totaling RMB 15 million to China Bank and RMB 20 million to China Merchants Bank for its subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. [7] Group 3 - The total external guarantee balance after the new guarantees is RMB 46.12 billion, representing 54.12% of the company's audited net assets for 2024 [27] - The guarantees are exclusively between the company and its subsidiaries, with no overdue guarantees or litigation-related guarantee amounts reported [27]

Core Viewpoint - Yifan Pharmaceutical reported that by the third quarter of 2025, the company expects to have ten pharmaceutical formulation products generating over 100 million RMB in revenue [2] Group 1 - As of the third quarter of 2025, the company anticipates ten products will exceed 100 million RMB in revenue [2] - The company will disclose the annual revenue of its main products in accordance with relevant laws and regulations [2]

Group 1: Major Transactions - Bohai Chemical is planning to sell 100% equity of Tianjin Bohai Petrochemical and acquire control of Anhui Taida New Materials through a combination of share issuance and cash payment, leading to a significant asset restructuring [1] - Zhongneng Electric is set to acquire 65% equity and debt from three companies, which may constitute a major asset restructuring but will not involve share issuance or change in control [4] - Hai Tai Development has decided to terminate the acquisition of controlling interest in Zhixueyun Technology due to disagreements on key terms, ensuring no adverse impact on normal business operations [5] Group 2: Performance Updates - Wen's shares reported a sales revenue of 3.324 billion yuan from meat chickens in November, marking a year-on-year increase of 10.18% [6] - Shuguang shares saw a 71.07% year-on-year increase in vehicle sales, totaling 207 units in November [6] - Muyuan shares experienced a decline in sales revenue from commodity pigs, reporting 9.39 billion yuan, a decrease of 20.43% year-on-year [6] - Pengding Holdings reported a 5.58% year-on-year decrease in consolidated revenue for November [6] Group 3: Industry Developments - Xiangxi Dairy reported a 6.3% month-on-month increase in fresh milk production in November, although it saw a year-on-year decline of 6.47% [7] - Baisheng Intelligent plans to acquire 51% equity in Zhongke Shengu, which focuses on the research and application of core technologies for embodied intelligent robots [7]

上纬新材：拟2600万元购买智元创新ARM嵌入式软件及通信中间件软件代码使用权 上纬新材公告称，公司拟与关联方智元创新签订《许可协议》，智元创新将其拥有的"ARM嵌入式软件 及通信中间件软件代码"授权公司使用，公司将支付智元创新合计2600万元的授权使用费。该交易构成 关联交易，但不构成重大资产重组。公司具身智能机器人业务当前处于开发阶段，尚未实现量产及规模 化销售，预计不会对2025年度业绩产生正向影响。公司目前已组建具身智能机器人研发团队，专注于面 向个人与家庭场景的产品开发（未面向工商业领域）。公司与关联方智元创新各自独立开展具身智能机 器人业务，应用场景不同，确保与关联方不构成重大不利影响的实质同业竞争。具身智能机器人行业发 展迅速，公司面临竞争加剧、技术迭代加速等巨大挑战，为加快产品开发速度，有必要通过本次交易， 进一步缩短产品开发周期，提升在新业务领域的综合竞争力。 今日焦点渤海化学：筹划出售渤海石化100%股权并购买泰达新材控制权，股票12月8日起停牌 渤海化学公告称，公司正在筹划出售天津渤海石化有限公司100%股权、通过发行股份及支付现金的方 式购买安徽泰达新材料股份有限公司的控制权。本次交易 ...